Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

25%

Ph early_phase_1

25%

Ph not_applicable

25%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated2

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (25.0%)

Phase 11 (25.0%)

Phase 21 (25.0%)

N/A1 (25.0%)

Trials by Status

completed125%

terminated250%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

NCT02194452

Clinical Trials (4)

Showing 4 of 4 trials

NCT01869725Phase 2

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Completed

NCT03001349Early Phase 1

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Terminated

NCT02177773Phase 1

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Terminated

NCT02194452Not Applicable

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4